Clinical Trials
4 trialsNCT03484923 2024-06-18
PLATforM
Novartis
Phase 2 Completed
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed
NCT02334748 2020-05-19
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
Novartis
Phase 3 Completed
NCT02911857 2018-08-20
An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes
Novartis
Phase 3 Completed